Healthcare

● The company simultaneously advanced an FDA meeting request tied to its solid-tumor T-cell engager program.

● Moleculin Biotech reported a 37% blinded remission rate in venetoclax-failed AML patients, a fresh interim look at its most important ongoing trial.

● Revelation Biosciences adopted a 10% stockholder rights plan, commonly called a poison pill, on July 10, 2026.

● Reviva Pharmaceuticals'Investmentcase rests almost entirely on one molecule: brilaroxazine, an experimental once-daily pill for schizophrenia.

● Sunshine Biopharma filed its second-quarter report on August 13, 2026, showing cash doubling to $13.7 million.

● Azitra is built on engineering Staphylococcus epidermidis, a bacterium naturally found on human skin, to produce useful proteins where needed.

Trust Stamp Inc reported a significant 22% increase in revenue for the first half of 2026, reflecting strong demand for its identity verification services primarily driven by engagements with clients in the telecommunications sector. The company generated $1.66 million in net recognized revenue, rising …